Key Takeaway: Jazz Pharmaceuticals will participate in the 25th Annual Needham Healthcare Conference on April 15, 2026. Company management will engage in a fireside chat, which will be available via an audio webcast. This event underscores Jazz's commitment to transparency and investor relations.
Price reaction · baseline $189.05 (2026-03-31 close) · hit after-hours · clean, no other JAZZ news in the window
day 0 close
-0.4%
Market Sentiment Analysis
POSITIVE FACTORS
Jazz Pharmaceuticals is actively engaging with investors.
Participation in a prominent healthcare conference highlights company visibility.
The company showcases its commitment to innovation in biopharma.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+46%
120-day peak, hindsight
Typical move
2.1%
average across 9 past catalysts
Lead asset
GWP42004
Phase 2 · Diabetes Mellitus, Type 2
Full Press Release Details
DUBLIN,April 1, 2026/PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq:JAZZ) today announced that the Company will participate in the 25thAnnual Needham Healthcare Conference. Company management will participate in a fireside chat on Wednesday, April 15, 2026, at 8:45 a.m. PT / 11:45 a.m. ET / 4:45 p.m. IST.
An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals website athttps://investor.jazzpharma.com/investors/events-presentations. A replay of the webcast will be archived on the website for 30 days.
About Jazz PharmaceuticalsJazz Pharmaceuticals plc (Nasdaq:JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease — often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visitwww.jazzpharmaceuticals.comfor more information.